bims-covirf Biomed News
on COVID19 risk factors
Issue of 2021–10–24
one paper selected by
Catherine Rycroft, BresMed



  1. Diabetes Metab Syndr. 2021 Oct 06. pii: S1871-4021(21)00328-3. [Epub ahead of print]15(6): 102308
       BACKGROUND AND AIMS: This meta-analysis aims to highlight the impact of cardio-metabolic comorbidities on COVID-19 severity and mortality.
    METHODS: A thorough search on major online databases was done for studies describing the clinical outcomes of COVID-19 patients. We used random-effects model to compute pooled estimates for critical or fatal disease.
    RESULTS: A total of 20,475 patients from 33 eligible studies were included. Maximum risk of development of critical or fatal COVID-19 disease was seen in patients with underlying cardiovascular disease [OR: 3.44, 95% CI: 2.65-4.48] followed by chronic lung disease, hypertension and diabetes mellitus. Of the total cases, 64% had one of the four comorbidities with the most prevalent being hypertension with a pooled prevalence of 27%.
    CONCLUSIONS: Presence of comorbidities like cardiovascular disease, chronic lung disease, hypertension and diabetes mellitus led to a higher risk of development of critical or fatal COVID-19 disease, with maximum risk seen with underlying cardiovascular disease.
    Keywords:  COVID-19; Cardiovascular disease; Diabetes mellitus; Hypertension; Meta-analysis; SARS-CoV-2; Systematic review
    DOI:  https://doi.org/10.1016/j.dsx.2021.102308